1. Carmo A, Rocha M, Pereirinha P, Tomé R, Costa E. Antifungals: From Pharmacokinetics to Clinical Practice. Antibiotics (Basel). 2023;12(5):884.
2. Cavassin, F.B.; Baú-Carneiro, J.L.; Vilas-Boas, R.R.; Queiroz-Telles, F. Sixty years of Amphotericin B: An Overview of the Main Antifungal Agent Used to Treat Invasive Fungal Infections.
Infect. Dis. Ther. 2021; 10: 115–147.
3. Rex J, Stevens D. Systemic Antifungal Agents. In: Mandell GL, Bennet JE, Dolin R (eds). Mandell, Douglas and Bennett’s Principles and Practise of Infectious Disease. Philadelphia: Churcill
Livingstone, 2010: 549-565.
4. Kanaujia R, Singh S, Rudramurthy SM. Aspergillosis: an Update on Clinical Spectrum, Diagnostic Schemes, and Management. Curr Fungal Infect Rep. 2023 :1-12. Epub ahead of print).
5. O’Grady N, McManus D, Briggs N, Azar MM, Topal J, Davis MW. Dosing implications for liposomal amphotericin B in pregnancy. Pharmacotherapy. 2023;43(5):452-462.
6. Zhong X, Yang J, Liu H, Yang Z, Luo P. Potential lipid-based strategies of amphotericin B designed for oral administration in clinical application. Drug Deliv. 2023;30(1):2161671.
7. Boulware DR, Atukunda M, Kagimu E, et al. Oral Lipid Nanocrystal Amphotericin B for Cryptococcal Meningitis: A Randomized Clinical Trial. Clin Infect Dis. 2023;77(12):1659-1667.
8. Johnson PC, Wheat LJ, Cloud GA, et al. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with
AIDS. Ann Intern Med 2002; 137:105-109.
9. Cornely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin B as initial therapy for invasive mold infection. A randomized trial comparing a high loading dose regimen with standard
dosing (Ambiload trial). Clin Infect Dis 2007; 44: 1289-1297.
10. Cornely OA, Leguay T, Maertens J, et al. Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia. J Antimicrob
Chemother 2017;72(8):2359-2367.
11. Stemler J, Mellinghoff SC, Khodamoradi Y, et al. Primary prophylaxis of invasive fungal diseases in patients with haematological malignancies: 2022 update of the recommendations of the
Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). J Antimicrob Chemother. 2023 ;78(8):1813-1826.
12. Bates DW, Su l, Yu DT, et al. Mortality and costs of acute renal failure associated amphotericin B therapy. Clin Infect Dis 2001; 32: 686-693.
13. Al-Khikani FHO. Amphotericin B as antiviral drug: Possible efficacy against COVID-19. Ann Thorac Med. 2020;15(3):118-124.
14. Roden MM, Nelson LD, Knudsen TA, et al. Triad of acute infusion related reactions associated with liposomal amphotericin B. Analysis of clinical and epidemiological characteristics. Clin
Infect Dis 2003; 36:1213-1220.
15. Ullmann AJ, Akova M, Herbrecht R et al. ESCMID guideline for the diagnosis and managemet of Candida diseases 2012: Adults with hematological malignancies and after hematopoetic stem
cell transplantation. Clin Microbiol Infect 2012; (Suppl 7):53-67.
16. Pilmis B, Jullien V, Sobel J, Lecuit M, Lortholary O, Charlier C. Antifungal drugs during pregnancy: an updated review. J Antimicrob Chemother. 2015;70(1):14-22.
17. Pappas PG, Kaufmann CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009;
48:503-35.
18. Gintjee TJ, Donnelley MA, Thompson GR 3rd. Aspiring Antifungals: Review of Current Antifungal Pipeline Developments. J Fungi (Basel). 2020;6(1):28.
19. Jović Z, Janković SM, Ružić Zečević D, et al. Clinical Pharmacokinetics of Second-Generation Triazoles for the Treatment of Invasive Aspergillosis and Candidiasis. Eur J Drug Metab Phar-
macokinet. 2019;44(2):139-157.
20. Ben-Ami R. Systemic Antifungal Therapy for Invasive Pulmonary Infections. J Fungi (Basel). 2023;9(2):144.
21. Boglione-Kerrien C, Zerrouki S, Le Bot A, et al. Can we predict the influence of inflammation on voriconazole exposure? An overview. J Antimicrob Chemother. 2023;78(11):2630-2636.
22. Herbrecht R, Denning DW, Paterson TE, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-415.
23. Walsh TJ7, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empiral antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med
2002; 346: 225-234.
24. Lockhart SR, Chowdhary A, Gold JAW. The rapid emergence of antifungal-resistant human-pathogenic fungi. Nat Rev Microbiol. 2023;21(12):818-832).
25. Ener B, Ergin Ç, Gülmez D,et al. Frequency of azole resistance in clinical and environmental strains of Aspergillus fumigatus in Turkey: a multicentre study. J Antimicrob Chemother. 2022;
77(7):1894-1898.
26. Maertens JA, Rahav G, Lee DG, et al. Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial. Lancet. 2021
;397(10273):499-509.
27. Zhang T, Shen Y, Feng S. Clinical research advances of isavuconazole in the treatment of invasive fungal diseases. Front Cell Infect Microbiol. 2022;12:1049959.
28. Maertens JA., Raad II, Marr KA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by aspergillus and other filamentous fungi (SECURE): a phase
3, randomised-controlled, non-inferiority trial. Lancet 2016; 387, 760–769.
29. Kullberg BJ, Viscoli C, Pappas PG, et al. Isavuconazole versus caspofungin in the treatment of candidemia and other invasive candida infections: The ACTIVE trial. Clin Infect Dis. 2019; 68,
1981–1989.
30. Gupta AK, Talukder M, Venkataraman M. Review of the alternative therapies for onychomycosis and superficial fungal infections: posaconazole, fosravuconazole, voriconazole, oteseconazole.
Int J Dermatol. 2022;61(12):1431-1441.
31. Azanza JR, Mensa J, Barberán J, et al. Recommendations on the use of azole antifungals in hematology-oncology patients. Rev Esp Quimioter. 2023 ;36(3):236-258.
32. Lewis RE, Kontoyiannis DP. Echinocandins: Caspofungin, Anidulafungin, Micafungin. In: Grayson ML (ed). Kucer’s The Use of Antibiotics. London: Hodder Arnold/ASM Press, 2010: 1736-
1763.
33. Cornely O, Vehreschild JJ, Vehreschild MJGT, et al. Phase II Dose Escalation Study of Caspofungin for Invasive Aspergillosis. Antimicrob Agents Chemother 2011; 55:5798-5803.
34. Fernández-Ruiz M, AguadoJM, Almirante B, et al. Initial use of echinocandins does not negatively influence outcome in Candida parapsilosis bloodstream infection: a propensity score
analysis. Clin Infect Dis 2014 58(10):1413-21.
35. Gómez-Gaviria M, Martínez-Álvarez JA, Chávez-Santiago JO, Mora-Montes HM. Candida haemulonii Complex and Candida auris: Biology, Virulence Factors, Immune Response, and
Multidrug Resistance. Infect Drug Resist. 2023;16:1455-1470.
36. Guo J, Chen Z, Kong C et al. Meta-analysis of echinocandins combined with trimethoprim-sulfamethoxazole for treatment of Pneumocystis pneumonia. J Chemother. 2023;35(3):181-187.
37. Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356: 2742-2482.
38. Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007;45:883–893.
39. Czajka KM, Venkataraman K, Brabant-Kirwan D, et al. Molecular Mechanisms Associated with Antifungal Resistance in Pathogenic Candida Species. Cells. 2023 ;12(22):2655.
40. Stover KR, Hawkins BK, Keck JM, Barber KE, Cretella DA. Antifungal resistance, combinations and pipeline: oh my! Drugs Context 2023;12:2023-7-1.
41. Hoenigl M, Sprute R, Egger M, et al. The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin. Drugs. 2021;81(15):1703-1729.